Commercialisation
FutureNeuro is focused on finding commercially relevant solutions for your industry needs. We work closely with the Technology Transfer Offices of each of our partner institutions to capture cutting edge innovation and invention and map out routes for commercialisation.
Spin-outs
To date the Centre has formed two spin out companies. Prof. Matthew Campbell spun out Exhaura in 2019 – a biotech company which primarily focuses on the use of gene therapy for the treatment of eye disease. They most recently have developed a gene therapy-based approach that can decrease intraocular pressure in pre-clinical models of glaucoma, a group of eye conditions that can cause vision loss and blindness due to damage to the optic nerve. The company is exploring a gene therapy approach for the treatment of epilepsy. Prof. Mark Cunningham spun out NeuroEblana in 2020. The company specialises in electrophysiology and neuroscience approaches to examine neuronal activity in brain regions relevant to disease processes.
IP Portfolio
The Centre is committed to creating an IP portfolio which is relevant to current and prospective industry partners. Our Lead Investigator team have, to date, filed/ been awarded nine patents, have assigned multiple IP portfolios to industry partners and regularly file Inventions Disclosure Forms arising from our basic research programme. When exploring new engagements opportunities with industry, we work closely to identify and prioritise projects which lead to the transfer of valuable IP. For more information, please contact our Business Development Lead, Julia Rakovets. Email juliarakovets@rcsi.ie.
